Subscribe
Michael Summersgill, partner at WilmerHale.
14 November 2024NewsAmericasSarah Speight

‘We took Ravgen head-on’: How we won zero-damages and others didn't

Michael Summersgill and his co-counsel at WilmerHale secured more favourable outcomes for their clients than others in a series of lawsuits brought by Ravgen over pre-natal screening tests, he tells Sarah Speight.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Biotechnology
Natera stung for $57m in prenatal screening clash
18 January 2024   Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.
article
LabCorp hit with further $100m in DNA test patent case
16 May 2023   Judge Albright awards punitive damages due to the 'intentional' nature of the infringement | Ravgen fails to secure a three-fold increase on damages awarded by a US jury last year.


Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024

Editor's picks

Americas
Amgen set for ‘at-risk’ launch of blockbuster eye drug biosimilar
24 October 2024
Asia
President Xi sends message to AIPPI’s World Congress
22 October 2024
Unified Patent Court
‘Every CMS filing is painful’: Notes from a Unified Patent Court dispute
26 September 2024
Unified Patent Court
Interview: Klaus Grabinski, UPC Court of Appeal president
24 September 2024
Unified Patent Court
‘Be prepared, and don’t assume at the UPC’: Christopher Stothers
12 September 2024
Unified Patent Court
Does the UPC offer a fresh take on patent validity?
5 September 2024

More on this story

Biotechnology
Natera stung for $57m in prenatal screening clash
18 January 2024   Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.
article
LabCorp hit with further $100m in DNA test patent case
16 May 2023   Judge Albright awards punitive damages due to the 'intentional' nature of the infringement | Ravgen fails to secure a three-fold increase on damages awarded by a US jury last year.

More on this story

Biotechnology
Natera stung for $57m in prenatal screening clash
18 January 2024   Dispute centres on genetic prenatal screening methodology | Ravgen’s $57 million award “significantly less” than the $410 million sought by Ravgen | Natera plans to appeal.
article
LabCorp hit with further $100m in DNA test patent case
16 May 2023   Judge Albright awards punitive damages due to the 'intentional' nature of the infringement | Ravgen fails to secure a three-fold increase on damages awarded by a US jury last year.

More features

Kathi Vidal to leave USPTO ahead of incoming Trump administration
Herbert Smith Freehills and Kramer Levin in $2bn merger talks
Teva fights for re-listing of inhaler patents at US appeals court
CRISPR patents revoked following Nobel Prize winners’ withdrawal
White & Case hires experienced litigator from A&O Shearman
President Trump 2.0: Five major areas to watch
China’s new policies on foreign investment in healthcare and biotech
Startup CFO’s betrayal is a lesson in preparing for the worst